164 related articles for article (PubMed ID: 37219080)
1. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Zhang C; Shen G; Li H; Xin Y; Shi M; Zheng Y; Wang M; Liu Z; Zhao Y; Zhao F; Ren D; Zhao J
Spec Care Dentist; 2024; 44(2):530-541. PubMed ID: 37219080
[TBL] [Abstract][Full Text] [Related]
2. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
4. Comment on: Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.
Somay E
Spec Care Dentist; 2024; 44(2):615-616. PubMed ID: 37515493
[No Abstract] [Full Text] [Related]
5. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials.
Qi WX; Tang LN; He AN; Yao Y; Shen Z
Int J Clin Oncol; 2014 Apr; 19(2):403-10. PubMed ID: 23605142
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
[TBL] [Abstract][Full Text] [Related]
7. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
[TBL] [Abstract][Full Text] [Related]
10. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
11. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
[TBL] [Abstract][Full Text] [Related]
12. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
13. Interventions for managing medication-related osteonecrosis of the jaw.
Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate and osteonecrosis of the jaw in osteoporosis: incidence and risk factors. Analysis of the French Pharmacovigilance Database.
Amigues C; Fresse A; Roux CH; Gauthier S; Vieillard MH; Drici MD; Breuil V;
Joint Bone Spine; 2023 Dec; 90(6):105599. PubMed ID: 37271278
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates-Preliminary data: Medical ozone gas insufflation in treating ONJ lesions.
Ripamonti CI; Maniezzo M; Boldini S; Pessi MA; Mariani L; Cislaghi E
J Bone Oncol; 2012 Dec; 1(3):81-7. PubMed ID: 26909261
[TBL] [Abstract][Full Text] [Related]
16. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review.
Bassan Marinho Maciel G; Marinho Maciel R; Linhares Ferrazzo K; Cademartori Danesi C
J Mol Med (Berl); 2024 Mar; 102(3):353-364. PubMed ID: 38302741
[TBL] [Abstract][Full Text] [Related]
17. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
18. The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.
Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
Ther Adv Med Oncol; 2019; 11():1758835919855235. PubMed ID: 31217825
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
20. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review.
de Boissieu P; Kanagaratnam L; Mahmoudi R; Morel A; Dramé M; Trenque T
Eur J Clin Pharmacol; 2017 May; 73(5):517-523. PubMed ID: 28188332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]